This article first appeared on GuruFocus .
-
Net Revenue:$45.2 million, a 40% increase year-over-year.
-
Gross Profit:$19.2 million, representing a 39% year-over-year growth.
-
Operating Expenses:$20.5 million, a year-over-year increase of $3.3 million.
-
Adjusted EBITDA:$5.1 million, an improvement of $2.8 million year-over-year.
-
Cash and Cash Equivalents:$822 million at the end of the quarter.
-
Share Repurchase Program:$50 million authorized by the Board.
-
International Revenue Growth:97% year-over-year growth, driven by Germany.
-
Canadian Retail Sales Growth:18% year-over-year, with Spinach brand leading in vapes.
-
Market Share in Edibles:20.8% market share, with gummies at 22.7%.
Release Date: May 11, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Cronos Group Inc ( NASDAQ:CRON ) delivered record net revenue and gross profit in Q1 2026, with international markets showing significant growth.
-
The Spinach brand achieved the number one market share position in vapes in Canada, capturing 9.8% total market share.
-
Cronos Israel delivered its ninth consecutive quarter of record net revenue, growing 53% year-over-year.
-
The company maintains a strong balance sheet with no debt and $822 million in cash and cash equivalents.
-
Cronos Group Inc ( NASDAQ:CRON ) announced a renewed $50 million share repurchase program, reflecting confidence in long-term business value.
Negative Points
-
Operating expenses increased by $3.3 million year-over-year, driven by higher G&A, sales and marketing, and R&D expenses.
-
The company faced supply constraints in the flower category, impacting market share growth.
-
There is uncertainty regarding the timing of the Cannatara acquisition closure, with potential delays into the third quarter.
-
Competitive dynamics in the Canadian market remain challenging, requiring strategic allocation of resources.
-
The company is still working on improving efficiencies and yields at the GrowCo expansion, indicating ongoing operational adjustments.
Q & A Highlights
Q: Can you provide an update on the GrowCo expansion and its current efficiency and throughput? A: Michael Gorenstein, Executive Chairman of the Board, President, Chief Executive Officer, stated that there has been a significant improvement in efficiency and progress from the last quarter. The company has achieved the necessary throughput and is now focusing on dialing in further efficiencies over the coming quarters.
Q: Regarding the extension on the long stop date for the Cannatara acquisition, is there a possibility that the closing might extend into the third quarter? A: Michael Gorenstein explained that the extension is primarily an abundance of caution. There have been no issues observed, and the process is progressing as expected. The company remains confident in the timeline.
Q: What is your perspective on the recent rescheduling news in the US and its impact on Cronos' plans? A: Michael Gorenstein expressed optimism about the rescheduling announcement, describing it as a significant milestone in the US regulatory environment. The company is monitoring developments and evaluating opportunities, particularly regarding interstate and international perspectives.
Q: Can you discuss the competitive dynamics in the Canadian market and how Cronos is protecting its margins? A: Michael Gorenstein noted that while competitive dynamics have been intense in the past, the company is now better positioned due to increased scale and improved cost absorption. This allows Cronos to compete effectively while maintaining flexibility.
Q: Could you comment on the market conditions in the Netherlands and any expected changes from the upcoming summary review? A: Michael Gorenstein mentioned that while competition is heating up, the market is growing. He does not anticipate significant changes from the summer review, which is expected to show positive program progress and support future growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
